ici 204,219 has been researched along with histamine phosphate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dollery, CT; Fuller, RW; O'Shaughnessy, KM; Taylor, IK | 1 |
1 review(s) available for ici 204,219 and histamine phosphate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ici 204,219 and histamine phosphate
| Article | Year |
|---|---|
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aerosols; Allergens; Bronchial Provocation Tests; Bronchoconstriction; Double-Blind Method; Drug Evaluation; Female; Forced Expiratory Volume; Histamine; Humans; Indoles; Leukotrienes; Male; Phenylcarbamates; Receptors, Immunologic; Skin Tests; Sulfonamides; Time Factors; Tosyl Compounds | 1991 |